Tekmira Pharmaceuticals has named Tammy Mullarky as its vice president of strategic planning and business development, and Peter Lutwyche as vice president of pharmaceutical development.
Mullarky previously served as senior vice president of crop biotechnology firm Targeted Growth. Before that, she was a senior executive at Epigenomics, a cancer molecular diagnostics company.
She holds an MA in science management from the Massachusetts Institute of Technology and a BA in chemistry from Whitman College.
Lutwyche was formerly with Protiva Biotherapeutics, which merged with Tekmira earlier this year (see RNAi News, 4/3/2008). Before that, he held a number of positions, most recently director of pharmaceutical development, at QLT.
He holds a PhD in chemistry from the University of British Columbia.
Alnylam Pharmaceuticals has named John Schmidt as its CSO.
Schmidt was previously vice president and US member of the Sanofi-Aventis Global Discovery Leadership Team. Prior to Aventis’ merger with Sanofi-Synthelabo, Schmidt was Aventis’ vice president and head of the respiratory and rheumatoid arthritis disease group. He also served as senior director of immunology and rheumatology at Merck Research Laboratories.
Schmidt holds an MD from the University of Pennsylvania.
Alnylam also said it has promoted Victor Kotelianski to the newly created position of senior vice president and distinguished Alnylam fellow. He was previously vice president of research.
Additionally, the company has promoted Antonin de Fougerolles to the position of vice president of research, immunology, metabolic, and viral disease; Susanna High to the position of vice president of business planning and program management; and Dinah Sah to the position of vice president of research, CNS, and oncology.
Intradigm has appointed Bryan Dunnivant, a principal at investment group Lilly Ventures, to its board of directors.
Dunnivant is joining the board in connection with Lilly Ventures’ participation in Intradigm’s Series B financing round (see related story, this issue).